Xiao Yanping, Hang Yaping, Chen Yanhui, Fang Xueyao, Cao Xingwei, Hu Xiaoyan, Luo Hong, Zhu Hongying, Zhu Wu, Zhong Qiaoshi, Hu Longhua
Jiangxi Provincial Key Laboratory of Medicine, Clinical Laboratory of the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Infect Drug Resist. 2020 Nov 24;13:4289-4296. doi: 10.2147/IDR.S269989. eCollection 2020.
The present study assessed risk factors and patient outcomes of bloodstream infection (BSI) caused by extended-spectrum β-lactamase (ESBL)-producing ().
A retrospective study was performed to analyze risk factors and patient outcomes of BSI caused by extended-spectrum β-lactamase-producing (ESBL-EC) in one Chinese tertiary hospital over a 7.5-year period. The clinical characteristics of patients infected with ESBL-producing and non-ESBL-producing were compared. Predictors of 30-day mortality in patients with BSI were also identified in our study.
The results of drug sensitivity showed that quinolones, aminoglycosides, -lactam/-lactamase inhibitor combinations (BLICs) and trimethoprim/sulfamethoxazole exhibited significant differences between the ESBL and non-ESBL groups. Of the 963 patients with BSI, 57.6% developed ESBL-EC. Multivariate analysis showed that biliary tract infection (BTI) [P<0.001,OR (95% CI):1.798 (1.334-2.425)], urinary tract obstructive disease [P=0.001,OR (95% CI):2.106 (1.366-3.248)], surgery within 3 months [P=0.002,OR (95% CI):1.591 (1.178-2.147)], hospitalization within 3 months [P<0.001,OR (95% CI):2.075 (1.579-2.725)], ICU admission [P=0.011,OR (95% CI):1.684 (1.124-2.522)] and history of cephalosporin use [P=0.006,OR (95% CI):3.097 (1.392-6.891)] were statistically significant. In mortality analysis, aCCI>2 [P=0.016,OR (95% CI): 2.453 (1.179-5.103)], gastrointestinal catheterization [P=0.004, OR (95% CI): 2.525 (1.333-4.782)] were significantly associated with 30-day mortality. According to Kaplan-Meier survival analysis, we found that in SOFA<2 group and SOFA≥2 group, the mortality rate of patients treated with BLICs were lower than that of carbapenems(P<0.05).
This study showed that BTI, urinary tract obstructive disease, surgery within 3 months, hospitalization within 3 months, ICU admission and cephalosporin exposure were independent risk factors for the emergence of ESBL-EC BSI. Analysis of risk factors for 30-day mortality revealed that the factors independently associated with a higher risk of mortality were aCCI>2, gastrointestinal catheterization. Compared to carbapenems, the BLICs had preferable effect to treat patients with ESBL-EC BSI. Notably, patients with severe illness were inlcined to use carbapenems, which affected the analysis results. Therefore, we suggest that BLICs could be recommended to treat mild patients with ESBL-EC bacteremia.
本研究评估产超广谱β-内酰胺酶(ESBL)的大肠埃希菌所致血流感染(BSI)的危险因素及患者预后。
进行一项回顾性研究,分析一家中国三级医院7.5年间产超广谱β-内酰胺酶的大肠埃希菌(ESBL-EC)所致BSI的危险因素及患者预后。比较产ESBL和不产ESBL的大肠埃希菌感染患者的临床特征。本研究还确定了BSI患者30天死亡率的预测因素。
药敏结果显示,喹诺酮类、氨基糖苷类、β-内酰胺/β-内酰胺酶抑制剂合剂(BLICs)和甲氧苄啶/磺胺甲恶唑在ESBL组和非ESBL组之间存在显著差异。在963例BSI患者中,57.6%发生ESBL-EC。多因素分析显示,胆道感染(BTI)[P<0.001,OR(95%CI):1.798(1.334-2.425)]、尿路梗阻性疾病[P=0.001,OR(95%CI):2.106(1.366-3.248)]、3个月内手术[P=0.002,OR(95%CI):1.591(1.178-2.147)]、3个月内住院[P<0.001,OR(95%CI):2.075(1.579-2.725)]、入住重症监护病房(ICU)[P=0.011,OR(95%CI):1.684(1.124-2.522)]和头孢菌素使用史[P=0.006,OR(95%CI):3.097(1.392-6.891)]具有统计学意义。在死亡率分析中,累积疾病评分指数(aCCI)>2[P=0.016,OR(95%CI):2.453(1.179-5.103)]、胃肠插管[P=0.004,OR(95%CI):2.